Indy Hematology Review

http://www.indyhematologyreview.com/

 

Indy Hematology Review
Avatar

Controversies and Recommendations for the Treatment of ALL and Lymphoblastic Lymphoma in 2023

By Indy Hematology Review FEATURING Wendy Stock
By Indy Hematology Review FEATURING Wendy Stock
588 views
April 19, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
2023
19:34
Indy Hematology Review

2023 Management of Long-Term Survivors of Hematologic Malignancies

Feat. S. Garofalo
26:05
Indy Hematology Review

Understanding and Managing Immune Effector Cell Toxicities in Hemato…

Feat. D. Reeves
73:56
Indy Hematology Review

Indy Hematology Review 2023: Expert Case Discussions

Feat. M. Wiemann, S. Usmani, J. Mikhael, M. Lunning, S. Treon, T. Phillips, J. Woyach
21:29
Indy Hematology Review

Indy Hematology Review 2023: Emerging Therapies in Hematologic Malig…

Feat. R. Birhiray
24:53
Indy Hematology Review

Emerging and Current Treatment of Amyloidosis and Waldenstrom’s Macr…

Feat. M. Gertz
26:02
Indy Hematology Review

Recognizing Toxicities of Oral Oncolytics in the Management of Hemat…

Feat. K. Orbaugh
31:33
Indy Hematology Review

Sickle Cell Disease and Clotting Disorders of the Blood in 2023

Feat. C. Kessler
31:51
Indy Hematology Review

Managing Newly Diagnosed MM in 2023

Feat. S. Usmani
22:30
Indy Hematology Review

Targets and Treatments of MPNs in 2023

Feat. R. Mesa
32:06
Indy Hematology Review

Current and Emerging Therapies for AML and MDS

Feat. R. Larson
24:33
Indy Hematology Review

Therapeutic Options in CLL in 2023: Choosing the Initial Therapy Wis…

Feat. J. Woyach
31:25
Indy Hematology Review

Jumping on a Moving Bullet Train: Emerging Treatments for Hodgkin Ly…

Feat. M. Lunning
34:28
Indy Hematology Review

Advancing Therapeutic Outcomes in Aggressive B and T Cell Lymphomas

Feat. T. Phillips
19:42
Indy Hematology Review

Beyond Hyperviscosity: 80 Years and Counting - Treatment of Waldenst…

Feat. S. Treon
18:27
Indy Hematology Review

DEBATE: Why Not to Transplant When MRD Has Been Achieved After Initi…

Feat. J. Mikhael
15:53
Indy Hematology Review

DEBATE: Transplanting the MRD- Myeloma Patients for a Deeper Remissi…

Feat. S. Usmani
06:33
Indy Hematology Review

Indy Hematology Review 2023: Take Home Messages for MDS & AML

Feat. R. Komrokji
06:36
Indy Hematology Review

Indy Hematology Review 2023: Recent Important Results for Adult ALL

Feat. C. Schiffer
04:15
Indy Hematology Review

Indy Hematology Review 2023: Plasma Cell Neoplasms and Amyloidosis U…

Feat. M. Gertz
28:07
Indy Hematology Review

Controversies and Recommendations for the Treatment of ALL and Lymph…

Feat. W. Stock
38:55
Indy Hematology Review

Managing Indolent and Mantle Cell Lymphomas With Targeted and Cellul…

Feat. G. Salles
24:21
Indy Hematology Review

Emerging Therapies for R/R CLL

Feat. W. Wierda
31:43
Indy Hematology Review

Myelofibrosis: Chronic and Blast Phase - 2023 Algorithms for Risk St…

Feat. A. Tefferi
24:37
Indy Hematology Review

Recent Updates on the Treatment of Polycythemia Vera

Feat. A. Fleischman
16:23
Indy Hematology Review

Updates on the Treatment of Myelofibrosis and FGFR-Mutated Myeloid N…

Feat. A. Fleischman
32:03
Indy Hematology Review

Emerging and Current Treatment of MM: What Should We Know and What S…

Feat. K. Anderson
31:16
Indy Hematology Review

Hematopoietic Stem Cell Transplantation: State of the Art in 2023

Feat. R. Childs
28:25
Indy Hematology Review

Managing the Benign Hematology Consult: Treatment Recommendations fo…

Feat. C. Kessler
28:41
Indy Hematology Review

Improving Outcomes With Current Therapies in AML and Acute Promyeloc…

Feat. M. Tallman
27:52
Indy Hematology Review

The Oracle of Apollo in Indianapolis: Prognosis and Treatment in MDS

Feat. R. Stone
27:16
Indy Hematology Review

Resistant or Recurrent CML and Prospective Discontinuation

Feat. R. Larson